Surveillance of ischemic stroke recurrence after prescription of EFIENT tablets (prasugrel)-JMDC Cohort Study

Not Applicable

Recruiting

• Conditions: Ischemic stroke

• Registration Number: JPRN-jRCT2031230289
• Lead Sponsor: Matsuoka Yomei

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1300

Inclusion Criteria

1) Patients who have prescription of prasugrel or clopidogrel within the enrollment period (December 24, 2021 to May 31, 2027). The cohort entry date: first prescription date of prasugrel or clopidogrel within the enrollment period.
2) Patients with acute ischemic stroke treated in hospital have diagnosis of atherothrombotic stroke or lacunar stroke during the past 30 days from the day before the cohort entry date.
3) Patients who have risk factors for ischemic stroke recurrence.
4) Patients who have medical records for the past 90 days from the day before the cohort entry date (Look back period).

Exclusion Criteria

1) Patients who have prescription of prasugrel or clopidogrel in the look back period.
2) No medical records from the day after the cohort entry date.
3) Patients who have prescriptions of prasugrel and clopidogrel on the cohort entry date.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ischemic stroke recurrence